3 ms·
It's way down there in the article, but Turing's distributor (Impax) is tampering with the generic approval process. They use a controlled distribution strateg
by paulmd 11y ago
It's way down there in the article, but Turing's distributor (Impax) is tampering with the generic approval process. They use a controlled distribution strategy where you need to buy it directly from them, and they won't sell it to anyone who uses it for approval testing. Without the namebrand drug, there's no way to prove that your generic is equally efficacious, and thus no generic approvals and no competition.
- daxelrod 11y agoWow, this should be illegal. Thanks for pointing it out.
- aianus 11y agoWhy can't you just go to a doctor or hospital and pay them a couple grand per pill and use that? Nobody has to know where you got it from...
- skj 11y agoBecause then you don't have an audit trail to use in your study documentation.
- aianus 11y agoI meant the manufacturer doesn't have to know (so they can't take revenge on the doctor/hospital). You can still have a hush-hush audit trail. Why is the original drug required anyways? Can't you prove it's the same without it? The details are all there in the public patent.
- rdtsc 11y agoJust a guess, I imagine they'd have to go through the whole new drug approval cycle as opposed to the show its bioactivity similar to existing one.
- skj 11y agoI'm pretty sure that "hush hush" audit trails for drug manufacturers are strictly illegal, would be found out, would bankrupt the company, etc.
- daxelrod 11y agoYou'd need a prescription to get it. And I don't believe it's legal for a person with the prescription to sell or give prescribed medicine to other other people.
- aianus 11y agoHire a researcher with toxoplasmosis ;)
- anigbrowl 11y agoEasier said than done, as toxoplasmosis promotes risky behavior of the sort that tends to be incompatible with a research career. Of course the real problem here is the subversion of the controlled-distribution mechanism to serve a private rather than a public end, a tragedy of the regulatory commons if you like. The basic idea here is good; you don't want drugs like thalidomide being freely prescribed because if they find their way to a pregnant woman consumption is likely to result in horrific birth deformities. This is an abstraction to many Americans because the FDA restricted Thalidomide early, but growing up in Europe I became aware of it from quite a young age because there was a small-but-distinct demographic cohort of people with characteristic deformities. But what's happening here is the drug manufacturer falsely claiming that there's a serious public health risk in order to get into the controlled-distribution system, and then using that to prevent any potential competitors from entering the market. I imagine that if the FDA had declined to make any of these drugs controlled-distribution then the strategic response would have been to hire a PR firm to plant stories about how the FDA doesn't care about medical vulnerabilities.